All News

    A Phase 1 Trial of Iadademstat Plus Vidaza Has Dosed a Patient With MDS

    January 29th 2025, 10:00pm

    Article

    The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with myelodysplastic syndrome.

    Opdivo Plus Yervoy Improves Outcomes in Metastatic Colorectal Cancer Subset

    January 29th 2025, 8:00pm

    Article

    The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer.

    Ovarian Cancer Teaches Hard Life Lessons

    January 29th 2025, 6:00pm

    Article

    Having a life-threatening disease reminds me daily to make the most of whatever time I have.

    A Cancer Institution is Seeking to Address Food Insecurity in Patients With Cancer

    January 29th 2025, 4:00pm

    Video

    Dr. Anna Arthur discusses the NOURISH trial, which aims to address food insecurity and malnutrition in patients with blood cancers undergoing treatment.

    FDA Accepts sNDA for Welireg in Advanced Pheochromocytoma and Paraganglioma

    January 29th 2025, 2:00pm

    Article

    The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

    Breaking Down the CONVERGE Study of NBTXR3 in Stage 3 Unresectable NSCLC

    January 28th 2025, 10:00pm

    Article

    The first participant has been dosed on the phase 2 CONVERGE study evaluating NBTXR3 in stage III, unresectable non–small cell lung cancer.

    Brukinsa May Improve Efficacy Versus Imbruvica in R/R CLL and SLL

    January 28th 2025, 7:59pm

    Article

    Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

    Life After MDS and Accomplishing Your Goals

    January 28th 2025, 6:00pm

    Article

    After a long and difficult journey, I finally published the book I set out to write as my legacy, overcoming cancer and the challenges of deafness.

    Identifying Drivers of Exceptional Response to Immunotherapy in Metastatic RCC

    January 28th 2025, 4:09pm

    Article

    In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell responses, among other factors.

    An Expert Shares Her Advice For Managing Side Effects in Cervical Cancer

    January 28th 2025, 2:00pm

    Video

    Dr. Ritu Salani shared her advice for patients undergoing advanced treatment options for their cervical cancer who are experiencing side effects.